(Q22241795)

7 February 2023

G. J. Hengstman

series ordinal

2

author given names

Gerald J D

author last names

Hengstman

1 reference

7 February 2023

A. Cakmak

series ordinal

3

author given names

Aysun

author last names

Çakmak

1 reference

7 February 2023

H. B. Thio

series ordinal

4

author given names

H Bing

author last names

Thio

1 reference

Multiple Sclerosis Journal

7 February 2023

language of work or name

English

0 references

publication date

27 February 2012

0 references

published in

0 references

volume

18

0 references

issue

12

0 references

page(s)

1705-1717

0 references

1 reference

https://api.crossref.org/works/10.1177/1352458512438239

Glatiramer acetate for multiple sclerosis

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1352458512438239

Multiple sclerosis: side effects of interferon beta therapy and their management

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1352458512438239

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1352458512438239

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1352458512438239

Multiple sclerosis--the plaque and its pathogenesis

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Interferon-beta mechanisms of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Interferon in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Strategies for managing the side effects of treatments for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Side effect profile of interferon beta-1b in MS: results of an open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Lipoatrophy in patients with multiple sclerosis on glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Progressive lipoatrophy after cessation of glatiramer acetate injections: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Dermal fibrosis and cutaneous necrosis after recombinant interferon-beta1a injection in a multiple sclerosis patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

A case of cutaneous necrosis during interferon-beta 1b (B-IFN) therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Focal neuropathy associated with cutaneous necrosis at the site of interferon-beta injection for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Severe necrotising cutaneous lesions complicating treatment with interferon beta-1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

An urticarial vasculitis case induced by glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Erythema elevatum et diutinum, multiple sclerosis and interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

[Panniculitis induced by interferon beta-1a vascular toxicity]

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Lupus-like reaction to interferon at the injection site: report of five cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Severe anaphylactic reaction to glatiramer acetate with specific IgE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Use of angiotensin receptor blockers after angioedema with an angiotensin-converting enzyme inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

An urticarial IgE-mediated reaction to interferon beta-1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Skin necrosis with subsequent formation of squamous cell carcinoma after subcutaneous interferon beta injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Reversible Alopecia Associated With Glatiramer Acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Cutaneous adverse events related to glatiramer acetate injection (copolymer-1, Copaxone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Großflächige kutan-subkutane Infiltrate als Nebenwirkung von Interferon-beta-Injektion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Localized lipoatrophy after prolonged treatment with copolymer 1

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Necrotising cutaneous lesions as a side effect of glatiramer acetate

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Interferon-beta injection site reaction: review of the histology and report of a lupus-like pattern

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Lupus erythematosus profundus (lupus panniculitis) induced by interferon-beta in a multiple sclerosis patient

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

[Cutaneous vasculitis with renal impairment complicating interferon-beta 1a therapy for multiple sclerosis]

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

[Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices]

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Subacute cutaneous lupus erythematosus associated with interferon beta-1a

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Cutaneous reactions to recombinant human interferon beta-1b: the clinical and histologic spectrum

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon beta-1b injections

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Severe urticaria due to recombinant interferon beta-1a

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Local reactions associated with subcutaneous injections of both beta-interferon 1a and 1b

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate.

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate.

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Cutaneous vasculitis associated with interferon beta-1b treatment for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Cutaneous reactions following subcutaneous beta-interferon-1b injection

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Calcified subcutaneous nodules: a long-term complication of interferon beta-1a therapy

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

New-onset psoriasis in a patient treated with interferon beta-1a

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Fixed drug eruption with interferon-beta-1b

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Cutaneous mucinoses complicating interferon beta-1b therapy

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Desensitization in interferon-beta1a allergy: a case report

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Necrotizing cutaneous lesions caused by interferon beta injections in a patient with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Embolia cutis medicamentosa following interferon beta injection

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Necrotizing skin lesions and NABs development in a multiple sclerosis patient treated with IFNbeta 1b

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

Necrotizing skin lesions with involvement of muscle tissue after subcutaneous injection of glatiramer acetate.

1 reference

https://api.crossref.org/works/10.1177%2F1352458512438239

7 January 2021

release_6govviir7jbbnbtbsfwaktaquq

Identifiers

DOI

10.1177/1352458512438239

0 references

Fatcat ID

0 references